David M. Cognetti
Experienced in Hyperparathyroidism

Dr. David M. Cognetti

Otolaryngology
1101 Chestnut Street, Floor 16, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Experienced in Hyperparathyroidism
1101 Chestnut Street, Floor 16, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Cognetti is an Otolaryngologist in Philadelphia, Pennsylvania. Dr. Cognetti is rated as an Experienced provider by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Salivary Duct Stones, Sialadenitis, Laryngectomy, and Gastrostomy. Dr. Cognetti is currently accepting new patients.

His clinical research consists of co-authoring 133 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Pittsburgh School Of Medicine
Residency
Thomas Jefferson University Hospitals
Specialties
Otolaryngology
Licenses
Otolaryngology in PA
Board Certifications
Otolaryngology - Head & Neck Surgery
Otolaryngology
Fellowships
UPMC-University of Pittsburgh Medical Center
Hospital Affiliations
Jefferson Abington Hospital
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Jefferson Otolaryngology (ENT) - Honickman Center
1101 Chestnut Street, Floor 16, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Cognetti has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Laryngeal Cancer
Hyperparathyroidism
Hyperthyroidism

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer
A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Early Phase 1
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 19, 2025
Intervention Type: Combination product, Biological
Study Drugs: Pembrolizumab, Cemiplimab
Study Phase: Phase 1/Phase 2
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
Enrollment Status: Completed
Publish Date: May 20, 2025
Intervention Type: Dietary supplement
Study Phase: Not Applicable
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Other
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Cisplatin, Carboplatin
Study Phase: Phase 2
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Combination product
Study Drugs: ASP-1929, Docetaxel, Cetuximab, Methotrexate, Paclitaxel
Study Phase: Phase 3
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Withdrawn
Publish Date: April 19, 2023
Intervention Type: Combination product, Biological
Study Drugs: RM-1995, Pembrolizumab
Study Phase: Phase 1
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Combination product
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

133 Total Publications

Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab.
Pathologic Treatment Effect and Survival in HPV-Negative HNSCC Following Neoadjuvant Nivolumab.
Journal: JAMA otolaryngology-- head & neck surgery
Published: July 31, 2025
Similar Doctors
Edmund A. Pribitkin
Distinguished in Hyperparathyroidism
Dr. Edmund A. Pribitkin
Otolaryngology
Distinguished in Hyperparathyroidism
Dr. Edmund A. Pribitkin
Otolaryngology

Jefferson Otolaryngology (ENT) - Honickman Center

1101 Chestnut Street, Floor 16, 
Philadelphia, PA 
 (0.2 miles away)
215-955-6760
Languages Spoken:
English, Portuguese, Russian, Spanish
See accepted insurances
Accepting New Patients

Edmund Pribitkin is an Otolaryngologist in Philadelphia, Pennsylvania. Dr. Pribitkin is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Thyroid Cancer, Anaplastic Thyroid Cancer, Papillary Thyroid Cancer, Thyroidectomy, and Septoplasty. Dr. Pribitkin is currently accepting new patients.

Elizabeth E. Cottrill
Distinguished in Hyperparathyroidism
Dr. Elizabeth E. Cottrill
Otolaryngology
Distinguished in Hyperparathyroidism
Dr. Elizabeth E. Cottrill
Otolaryngology

Jefferson Otolaryngology – Torresdale

3998 Red Lion Road, Suite 203, 
Philadelphia, PA 
 (12.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Cottrill is an Otolaryngologist in Philadelphia, Pennsylvania. Dr. Cottrill is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. Her top areas of expertise are Thyroid Nodule, Thyroid Cancer, Hyperparathyroidism, Thyroidectomy, and Parathyroidectomy. Dr. Cottrill is currently accepting new patients.

Distinguished in Hyperparathyroidism
Dr. Jeffrey S. Driben
Otolaryngology
Distinguished in Hyperparathyroidism
Dr. Jeffrey S. Driben
Otolaryngology

Ent Head And Neck Specialists, PC

985 Berkshire Blvd, Suite 101, 
Wyomissing, PA 
 (51.2 miles away)
610-374-5599
Languages Spoken:
English
See accepted insurances

Jeffrey Driben is an Otolaryngologist in Wyomissing, Pennsylvania. Dr. Driben is rated as a Distinguished provider by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Thyroid Nodule, Infant Hearing Loss, Familial Isolated Hyperparathyroidism, and Parathyroid Hyperplasia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cognetti's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 17 Advanced Conditions
View All 31 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile